Pancreatic Cancer Research

ResearcherBoston UniversityActive in the last 2 years

Teviah Erik Sachs

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8560-3606; OpenAlex author ID A5090739854. Sources: OpenAlex.

Their work

Papers
12 (first author 3, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
14
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: 3 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 12

  1. How Collaboration Between Surgeons and Medical Oncologists Affects Outcomes for Patients with Pancreatic Cancer. Last author DOI 10.1016/j.jcjq.2026.06.001↗
  2. The Evaluation of Gallstone Disease in the Year Before Pancreatic Cancer Diagnosis. Last author DOI 10.1016/j.jss.2023.06.017↗
  3. Socioeconomic Mediation of Racial Segregation in Pancreatic Cancer Treatment and Outcome Disparities. Last author DOI 10.1097/sla.0000000000005543↗
  4. A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer. First author DOI 10.1245/s10434-023-13281-1↗
  5. The impact of upper gastrointestinal surgical volume on short term pancreaticoduodenectomy outcomes for pancreatic adenocarcinoma in the SEER-Medicare populati… Last author DOI 10.1016/j.hpb.2021.10.015↗
  6. The Impact of Residential Segregation on Pancreatic Cancer Diagnosis, Treatment, and Mortality. Last author DOI 10.1245/s10434-020-09218-7↗
  7. ASO Author Reflections: The Impact of Residential Segregation on Pancreatic Cancer Diagnosis, Treatment, and Mortality. Last author DOI 10.1245/s10434-020-09257-0↗
  8. ASO Editorial: Nodal Status as a Clinical Tool in the Treatment of Pancreatic Cancer. First author DOI 10.1245/s10434-020-09553-9↗
  9. Opportunity Lost? Diagnostic Laparoscopy in Patients with Pancreatic Cancer in the National Surgical Quality Improvement Program Database. Last author DOI 10.1007/s00268-018-4855-8↗
  10. Impact of Race, Insurance Status, and Primary Language on Presentation, Treatment, and Outcomes of Patients with Pancreatic Adenocarcinoma at a Safety-Net Hosp… Last author DOI 10.1016/j.jamcollsurg.2019.05.027↗
  11. Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2017.12.004↗
  12. Conditional survival in pancreatic cancer: better than expected. First author DOI 10.1111/j.1477-2574.2011.00379.x↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Susanna W.L. de Geus · 5 shared papers, 2018–2023 · strength 0.92
  2. Marianna V. Papageorge · 4 shared papers, 2021–2023 · strength 0.88
  3. Jennifer F. Tseng · 6 shared papers, 2018–2023 · strength 0.81
  4. Michael R. Poulson · 3 shared papers, 2021–2023 · strength 0.62
  5. Barbara Aldana Blanco · 2 shared papers, 2021 · strength 0.38
  6. Anays Murillo · 1 shared paper, 2026 · strength 0.33
  7. Mark P. Callery · 2 shared papers, 2011–2018 · strength 0.12
  8. Tara Sotsky Kent · 2 shared papers, 2011–2018 · strength 0.12
  9. Munizay Paracha · 1 shared paper, 2019 · strength 0.11
  10. Praveen Sridhar · 1 shared paper, 2019 · strength 0.10
  11. Gyulnara G. Kasumova · 1 shared paper, 2018 · strength 0.08
  12. Arthur James Moser · 1 shared paper, 2018 · strength 0.08
  13. Alexander L. Vahrmeijer · 1 shared paper, 2018 · strength 0.08
  14. Charles M. Vollmer · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.